TY - JOUR
T1 - Are anthracycline-based regimens truly indicated to be the standard chemotherapy regimen for thymic carcinoma?
AU - Hirai, Fumihiko
AU - Toyozawa, Ryo
AU - Nosaki, Kaname
AU - Seto, Takashi
N1 - Publisher Copyright:
© 2015 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
PY - 2016
Y1 - 2016
N2 - Introduction: Thymic carcinoma (TC) is an exceptionally rare form of tumor that differs from thymoma by virtue of its very poor prognosis. The difficulties associated with conducting prospective trials involving rare diseases such as TC limit the evidence that can be applied to their treatment. To the extent possible, however, all medical treatment should be evidence based. Methods: We reviewed the clinical results regarding chemotherapy and thymic epithelial malignancies, which include invasive thymoma and TC. We conducted a search of the PubMed database to extract all the chemotherapeutic clinical trials from January 1990 to December 2014. The search included the terms chemotherapy, thymic malignancy, thymoma, and thymic carcinoma and all English-language publications. Results: From the initial total of 248 articles, we excluded articles that were only in abstract form, review articles, and case reports. In addition, to focus on cytotoxic therapies, we excluded articles on molecular target therapy for TC from our study. After the exclusion criteria were applied, 31 articles remained; they included prospective and retrospective trials. Conclusions: This study assessed the reliable and assessable data on the chemotherapy regimens for TC to identify the evidence-based recommendations. The results indicate that the only recommended anthracycline-containing regimen would be carboplatin plus amrubicin-not the combination of cisplatin, doxorubicin, vincristine, and cyclophosphamide- and that the recommended regimens without anthracycline would be carboplatin plus paclitaxel and cisplatin plus docetaxel.
AB - Introduction: Thymic carcinoma (TC) is an exceptionally rare form of tumor that differs from thymoma by virtue of its very poor prognosis. The difficulties associated with conducting prospective trials involving rare diseases such as TC limit the evidence that can be applied to their treatment. To the extent possible, however, all medical treatment should be evidence based. Methods: We reviewed the clinical results regarding chemotherapy and thymic epithelial malignancies, which include invasive thymoma and TC. We conducted a search of the PubMed database to extract all the chemotherapeutic clinical trials from January 1990 to December 2014. The search included the terms chemotherapy, thymic malignancy, thymoma, and thymic carcinoma and all English-language publications. Results: From the initial total of 248 articles, we excluded articles that were only in abstract form, review articles, and case reports. In addition, to focus on cytotoxic therapies, we excluded articles on molecular target therapy for TC from our study. After the exclusion criteria were applied, 31 articles remained; they included prospective and retrospective trials. Conclusions: This study assessed the reliable and assessable data on the chemotherapy regimens for TC to identify the evidence-based recommendations. The results indicate that the only recommended anthracycline-containing regimen would be carboplatin plus amrubicin-not the combination of cisplatin, doxorubicin, vincristine, and cyclophosphamide- and that the recommended regimens without anthracycline would be carboplatin plus paclitaxel and cisplatin plus docetaxel.
UR - http://www.scopus.com/inward/record.url?scp=84959353092&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959353092&partnerID=8YFLogxK
U2 - 10.1016/j.jtho.2015.09.007
DO - 10.1016/j.jtho.2015.09.007
M3 - Article
C2 - 26762746
AN - SCOPUS:84959353092
VL - 11
SP - 115
EP - 121
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
SN - 1556-0864
IS - 1
ER -